| Active, not recruiting | 2 | 171 | Europe, US, RoW | eftilagimod alpha, IMP321, efti, eftilagimod alfa, pembrolizumab (KEYTRUDA®), MK-3475 | Immutep S.A.S., Merck Sharp & Dohme LLC | HNSCC | 03/24 | 03/25 | | |
DigiNet, NCT05818449: Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation |
|
|
| Active, not recruiting | N/A | 850 | Europe | DigiNet intervention | University of Cologne, Gemeinsamer Bundesausschuss (G-BA), AOK Rheinland/Hamburg, AOK Nordwest, BARMER, University Hospital, Essen, Charite University, Berlin, Germany, Berlin Institute of Health, Helios Klinikum Emil von Behring, University Hospital Carl Gustav Carus, Deutsche Krebsgesellschaft e.V., Berufsverband der Niedergelassenen Hämatologen und Onkologen in Deutschland e.V., AOK Bundesverband, FOM Hochschule für Oekonomie und Management, University Medicine Greifswald, Technische Universität Dresden | Non-small Cell Lung Cancer Stage IV | 03/25 | 03/25 | | |
